Sage’s Search for Lifeline Ran Into Defiant Biogen CEO
  Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
  Biogen: Investors Are Missing The Bigger Picture
  Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
  Biogen begins Phase III trial for primary membranous nephropathy
  Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma
  Biogen races into phase 3 with Spinraza follow-up
  Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations